Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2022 08:33 ET | Source: IO Biotech

IO Biotech Hosting Key Opinion Leader Webinar Series

Part 1: A New Way to Kill Tumors–IO102-IO103 Phase 3 Trial in Combination with Anti-PD-1 in Advanced Melanoma Thursday, April 28th @ 12:30pmET NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- IO...
April 12, 2022 08:30 ET | Source: IO Biotech

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
April 08, 2022 16:15 ET | Source: IO Biotech

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

Updated Data as of December 1, 2021 from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic MelanomaThree-year Survival Probability of 73%Subgroup analyses including patients...
March 31, 2022 16:15 ET | Source: IO Biotech

IO Biotech Announces Year-End Results for 2021

--Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma to be Presented at AACR in April-- -- Began Patient...
March 08, 2022 16:30 ET | Source: IO Biotech

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

Clinical Update from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma from New Data Cut as of December 1, 2021 Multiple Subgroup Analyses Will be Presented for...
March 04, 2022 08:00 ET | Source: IO Biotech

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
March 03, 2022 16:05 ET | Source: IO Biotech

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
December 09, 2021 11:05 ET | Source: IO Biotech

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel immune-modulating cancer therapies based on its T-win® technology,...
December 06, 2021 08:00 ET | Source: IO Biotech

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
November 09, 2021 11:06 ET | Source: IO Biotech

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock,...